Comparison tool
Compare peptides
Pick up to three compounds. Useful for deciding whether two peptides in a stack actually do different things, or whether you're paying twice for the same pathway.
Select up to three (1/3)
| Attribute | |
|---|---|
| Category | Recovery & repair |
| Evidence grade | Emerging |
| Also known as | Body Protection Compound 157, PL 14736 |
| Mechanism | Appears to upregulate growth-hormone receptor expression in tendon fibroblasts and promote angiogenesis via the VEGFR2–Akt–eNOS pathway, accelerating the formation of new blood vessels at an injury site. It also modulates nitric oxide signalling and appears protective of the gut lining. |
| Key benefits | Faster tendon, ligament and muscle healing in rodent models · Protective effect on the gastrointestinal lining, including NSAID-induced damage · Reduced local inflammation around injury sites · Anecdotal relief from tendinopathy and joint pain |
| Side effects | Injection-site irritation · Transient dizziness or nausea · Unknown long-term safety profile |
| Half-life | Approximately 4 hours (stable oral form debated) |
| Administration | Subcutaneous injection; oral capsules used for gut-specific goals |
| Dosing overview | Commonly cited in literature at 200–500 mcg once or twice daily for 4–8 weeks |
| Storage | Lyophilised powder refrigerated; reconstituted vials 2–8 °C, used within ~30 days |
| Legal status | Not FDA-approved. Research-chemical status in most countries; prohibited in sport. |
Dosing figures reflect published literature and commonly reported community protocols. They are informational only.